Restrictive cardiomyopathy (RCM) is the least common form of cardiomyopathy (2–5% of cases), characterized by myocardial stiffness with impaired ventricular filling, non-dilated ventricles, preserved systolic function, and marked biatrial enlargement. [1-2] The underlying pathophysiology involves a rapid rise in ventricular pressure with only small increases in filling volume, leading to diastolic heart failure. [1] Disease-modifying treatments are available only for cardiac amyloidosis and, partially, for iron overload cardiomyopathy; otherwise, management is largely supportive with diuretics and eventual cardiac transplantation. [1][3]
1. History
- Dyspnea on exertion is the most common presenting symptom; exercise intolerance occurs due to inability of the ventricle to fill adequately at higher heart rates [3]
- Fatigue, lower extremity edema, abdominal distension (ascites), and weight gain
- Chest pain may occur but is infrequent [3]
- Palpitations or syncope (arrhythmias, particularly atrial fibrillation)
- Timing: insidious onset with progressive worsening; ask about prior cardiac surgery, radiation therapy, chemotherapy (anthracyclines)
- In children: failure to thrive, fatigue, fainting, sudden death may be the first presentation [4]
- Ask about bilateral carpal tunnel syndrome, lumbar spinal stenosis, biceps tendon rupture (clues to ATTR amyloidosis) [5]
- Important negatives: absence of prior pericarditis, absence of pleuritic chest pain
2. Alarm Features
- Syncope or presyncope — suggests arrhythmia or severely impaired cardiac output [6]
- Sudden cardiac death — particularly in pediatric RCM (two-year survival <50% in children) [7-8]
- Rapidly progressive dyspnea, orthopnea, or anasarca
- New conduction disease (AV block, bundle branch block) — suggests infiltrative process (amyloidosis, sarcoidosis) [3]
- Signs of low cardiac output: cool extremities, altered mental status, hypotension
- Thromboembolic events (stroke, peripheral embolism) — high incidence in RCM [3-4]
- Severe or irreversible pulmonary hypertension — may preclude transplantation [8]
3. Medications
- Diuretics (loop diuretics): Mainstay of symptomatic treatment; must be used judiciously — overdiuresis in a nondistensible ventricle causes hypotension, prerenal azotemia, and low-output state [3][9]
- Beta-blockers and calcium channel blockers: Use with caution; may not be tolerated due to dependence on heart rate for cardiac output [8]
- ACE inhibitors / ARBs: May cause hypotension; data supporting benefit in RCM are lacking [2][8]
- Anticoagulation: Recommended for atrial fibrillation and high thromboembolic risk; antithrombotic therapy recommended at diagnosis in pediatric RCM [3][8]
- Antiarrhythmics: Rhythm control preferred over rate control for atrial fibrillation to preserve atrial contractility and diastolic filling [3]
- Digoxin: Contraindicated in cardiac amyloidosis (increased sensitivity to toxicity)
- Disease-specific agents: Tafamidis (ATTR-CM), bortezomib-based chemotherapy (AL amyloidosis), phlebotomy/iron chelation (hemochromatosis), agalsidase beta (Fabry disease) [10]
4. Diet
- Sodium restriction: 2–4 g/day recommended [3]
- Fluid restriction: ~2 L/day [3]
- Avoid excessive alcohol intake
- Long-term: maintain adequate nutrition; in children, monitor for failure to thrive [4]
5. Review of Systems
- Cardiovascular: Dyspnea, orthopnea, PND, edema, palpitations, syncope
- GI: Abdominal distension (ascites), early satiety, hepatomegaly, right upper quadrant pain
- Neurologic: Peripheral neuropathy, autonomic dysfunction (amyloidosis clue) [5]
- Musculoskeletal: Bilateral carpal tunnel syndrome, lumbar spinal stenosis, biceps tendon rupture (ATTR clues) [5]
- Dermatologic: Skin thickening (scleroderma), rash (sarcoidosis)
- Ophthalmologic: Vitreous opacities (hereditary ATTR)
- Pulmonary: Cough, hemoptysis (pulmonary congestion, sarcoidosis)
6. Collateral History and Family History
- Family history of cardiomyopathy, sudden cardiac death, or heart failure — genetic RCM shares mutations with HCM (MYH7, TNNI3, TNNT2, ACTC1) [7][11]
- Less than half of RCM patients have a positive family history, but up to 75% of "idiopathic" RCM cases show evidence of genetic causation when comprehensive testing is performed [12]
- Family history of amyloidosis, neuropathy, or early-onset heart failure (hereditary ATTR)
- History of chronic inflammatory disease (AA amyloidosis) [13]
- Occupational/environmental exposures: radiation therapy, chemotherapy
- Social context: functional status, ability to perform ADLs
7. Risk Factors
- Amyloidosis (most common secondary cause): age >60, African American descent (Val122Ile TTR variant), monoclonal gammopathy [13-14]
- Radiation therapy to the chest (Hodgkin lymphoma, breast cancer) [14]
- Chemotherapy (anthracyclines) [14]
- Hemochromatosis: hereditary or transfusion-related iron overload [15]
- Sarcoidosis: young to middle-aged adults, African American predilection [15]
- Storage diseases: Fabry disease (X-linked), glycogen storage disorders [3]
- Endomyocardial fibrosis: tropical regions (sub-Saharan Africa, South America) [14]
- Genetic mutations: sarcomeric genes (autosomal dominant inheritance) [11]
- Connective tissue diseases: scleroderma [14]
8. Differential Diagnosis
- Constrictive pericarditis — the critical "cannot-miss" mimic; potentially curable with pericardiectomy. Key distinguishing features: tissue Doppler e′ >8 cm/s in constriction (reduced in RCM), respirophasic septal shift present in constriction, discordant ventricular pressures on catheterization [3][10]
- Hypertrophic cardiomyopathy with restrictive physiology — may overlap genetically and phenotypically [7]
- Hypertensive heart disease with HFpEF — must be excluded [3]
- Cardiac tamponade — pericardial effusion with hemodynamic compromise
- Right heart failure from pulmonary hypertension or severe tricuspid regurgitation [16]
- Intrinsic liver disease — can mimic right-sided congestion [16]
- Valvular heart disease (mitral stenosis, tricuspid stenosis) — inlet obstruction must be excluded [6]
The following figure illustrates the diagnostic approach to differentiating constrictive pericarditis from restrictive cardiomyopathy across multiple imaging modalities:
9. Past Medical History
- Prior cardiac surgery or pericarditis (risk for constriction — must differentiate)
- History of malignancy and chest radiation or anthracycline exposure [14]
- Known amyloidosis, sarcoidosis, hemochromatosis, Fabry disease
- Chronic inflammatory conditions (rheumatoid arthritis, IBD — AA amyloidosis risk) [13]
- Multiple orthopedic surgeries, carpal tunnel syndrome (ATTR clue) [5]
- Prior thromboembolic events
- Chronic kidney disease (may complicate management)
10. Physical Exam
- Vital signs: Tachycardia, low-normal blood pressure; hypotension may develop with treatment
- JVP: Elevated with prominent x and y descents; Kussmaul's sign may be present (though classically more associated with constriction) [3][17]
- Cardiac: Normal S1/S2; loud S4 gallop is typical; S3 may also be present; apical impulse usually palpable and mildly displaced [3]
- Lungs: Pulmonary rales, pleural effusions [10]
- Abdomen: Hepatomegaly (pulsatile), ascites [3]
- Extremities: Marked pedal edema [3]
- Murmurs: Mitral and tricuspid regurgitation frequently present [3]
- Neurologic: Peripheral neuropathy (amyloidosis)
- Skin: Periorbital purpura (AL amyloidosis), macroglossia
11. Lab Studies
- BNP / NT-proBNP: Typically elevated; significantly higher in RCM (>600 pg/mL) than constrictive pericarditis (~124 pg/mL median), though overlap exists [6][14]
- Troponin: May be chronically elevated in infiltrative disease
- CBC, CMP: Baseline; assess renal/hepatic function
- Serum and urine protein electrophoresis (SPEP/UPEP) with immunofixation: Screen for monoclonal protein (AL amyloidosis) [14]
- Free light chains: Kappa/lambda ratio for AL amyloidosis
- Iron studies: Ferritin, transferrin saturation (hemochromatosis)
- ACE level: If sarcoidosis suspected
- Alpha-galactosidase A: If Fabry disease suspected
- Genetic testing: Yield up to 60% in familial RCM; panels overlap with HCM/DCM genes [11-12]
12. Imaging
- Chest X-ray: Normal ventricular silhouette with enlarged atria; pulmonary congestion, Kerley B lines, pleural effusions [3][17]
- Echocardiography (first-line): Biatrial enlargement (pathognomonic), normal/small LV cavity, preserved LVEF, diastolic dysfunction with restrictive filling pattern (short E deceleration time <150 ms, E/A >2), reduced tissue Doppler e′ velocity (<8 cm/s) [3][6][10]
- Cardiac MRI (CMR): Tissue characterization — late gadolinium enhancement patterns, T1 mapping, extracellular volume fraction; critical for distinguishing amyloidosis, sarcoidosis, hemochromatosis, and fibrosis [1-2]
- Bone scintigraphy (Tc-99m PYP/DPD/HMDP): High sensitivity/specificity for ATTR cardiac amyloidosis when monoclonal protein is absent [5]
- Cardiac CT: Useful for pericardial thickness assessment (to exclude constriction) [10]
- Cardiac catheterization: Demonstrates elevated and equalized diastolic pressures, "dip-and-plateau" or "square root sign"; concordant respirophasic ventricular pressure changes (vs. discordant in constriction) [16]
The following figure outlines the diagnostic algorithm for ATTR cardiac amyloidosis, the most common secondary cause of RCM:
13. Special Tests
- Endomyocardial biopsy: May be required when noninvasive workup is inconclusive; Congo red staining with apple-green birefringence confirms amyloidosis [1][17]
- Tissue Doppler e′ velocity: The single most useful echocardiographic parameter to distinguish RCM (e′ <8 cm/s) from constrictive pericarditis (e′ >8 cm/s) [3][10]
- Speckle-tracking strain: "Apical sparing" pattern on bull's-eye plot is characteristic of cardiac amyloidosis [5]
- Right heart catheterization: Assess pulmonary vascular resistance (critical for transplant candidacy) [8]
- Genetic testing: Comprehensive cardiomyopathy gene panels; TTR gene sequencing for hereditary ATTR [11]
14. ECG
- Biatrial enlargement: Wide, increased-amplitude P waves [14]
- Low QRS voltage: Especially with increased wall thickness on echo — classic discordance suggesting amyloidosis [3][14]
- Pseudoinfarction pattern: Q waves in anterior leads without coronary disease (amyloidosis, sarcoidosis) [3]
- Nonspecific ST-T wave abnormalities [17]
- Bundle branch block: Present in 20–30% of RCM; suggests infiltrative process [14]
- AV conduction disease: Raises concern for sarcoidosis or amyloidosis [3]
- Atrial fibrillation: Common complication [3][10]
15. Assessment
RCM is a heterogeneous group of diseases unified by restrictive diastolic physiology with non-dilated ventricles and biatrial enlargement. [1] The most common secondary cause is cardiac amyloidosis, which is increasingly recognized in elderly patients with HFpEF. [3] Prognosis is generally poor: approximately one-third of adults with idiopathic RCM do not survive more than five years, and risk doubles with male sex, left atrial dimension >60 mm, age >70, and higher NYHA class. [3] Pediatric RCM carries an even worse prognosis, with >50% requiring transplant or dying within two years. [8] The critical diagnostic challenge is distinguishing RCM from constrictive pericarditis, as the latter is surgically curable. [3][18] Atypical presentations include isolated arrhythmias, thromboembolic events, or syncope as the first manifestation. [6]
16. Treatment Plan
Initial stabilization (ED)
- IV diuretics for acute decompensation; avoid aggressive diuresis (risk of low-output state) [3]
- Treat hemodynamically significant arrhythmias; cardiovert atrial fibrillation if unstable
- Supplemental oxygen for hypoxemia
Ongoing management
- Diuretics: Judicious loop diuretics for volume overload; monitor closely for overdiuresis [3][9]
- Sodium restriction (2–4 g/day) and fluid restriction (~2 L/day) [3]
- Anticoagulation: For atrial fibrillation and/or high thromboembolic risk [3]
- Rhythm control: Preferred over rate control for atrial fibrillation to maintain atrial contribution to filling [3]
- Avoid or use with extreme caution: Beta-blockers, CCBs, ACE inhibitors/ARBs, digoxin (especially in amyloidosis) [2][8]
Disease-specific therapy: [1][10]
- AL amyloidosis: Bortezomib-based chemotherapy ± stem cell transplant
- ATTR amyloidosis (wild-type): Tafamidis
- ATTR amyloidosis (hereditary): Tafamidis; heart ± liver transplant
- Hemochromatosis: Phlebotomy, iron chelation
- Fabry disease: Agalsidase beta enzyme replacement
- Sarcoidosis: Immunosuppression
- Endomyocardial fibrosis: Steroids, warfarin, endocardiectomy
Advanced therapies
- ICD: Consider for arrhythmia risk in select etiologies (amyloidosis, sarcoidosis, Friedreich's ataxia) [10]
- Cardiac transplantation: Definitive treatment for end-stage disease; timing is controversial, and pulmonary hypertension may preclude candidacy [3][8-9]
- VAD support: Challenging due to small LV cavity; modified cannulation techniques reported in select centers [8]
17. Disposition
Admit if
- New diagnosis with hemodynamic instability or significant volume overload
- Acute decompensated heart failure requiring IV diuretics
- New arrhythmia (atrial fibrillation with rapid ventricular response, high-degree AV block)
- Syncope or presyncope
- Thromboembolic event
- Evidence of low cardiac output or end-organ dysfunction
Observation if
Discharge if
- Known RCM with mild symptoms, stable volume status, and reliable follow-up
- Ensure cardiology follow-up is arranged
Consult
- Cardiology (always) — for echocardiography, advanced imaging, and management
- Advanced heart failure / transplant team — early referral for transplant evaluation [8]
- Hematology — if AL amyloidosis suspected
- Genetics — for familial RCM or hereditary ATTR [11]
18. Follow Up / Return Precautions
- Follow-up: Cardiology within 1–2 weeks after ED visit or discharge; serial echocardiography and monitoring of pulmonary vascular resistance [8]
- Daily weights: Instruct patients to weigh daily and report weight gain >2–3 lbs in 24 hours or >5 lbs in a week
- Return immediately for: Worsening shortness of breath, new or worsening edema, syncope or near-syncope, palpitations, chest pain, signs of stroke or peripheral embolism
- Expected course: Progressive disease in most etiologies; disease-modifying therapy available only for amyloidosis and hemochromatosis [1]
- Family screening: First-degree relatives should be evaluated with echocardiography and considered for genetic testing given high heritability [11-12]
- Avoid NSAIDs and excessive fluid intake
- Medication adherence: Emphasize importance of diuretic compliance and dietary restrictions
References
1. Restrictive Cardiomyopathy: Definition and Diagnosis. — Rapezzi C, Aimo A, Barison A, et al. European Heart Journal. 2022.
2. Cardiomyopathy: A Guide for Primary Care. — Coppiano J, Carrasco M, Asif I. American Family Physician. 2026.
3. Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 1 of a 2-Part Series. — Pereira NL, Grogan M, Dec GW. Journal of the American College of Cardiology. 2018.
4. Familial restrictive cardiomyopathy. — National Library of Medicine (MedlinePlus) 2019.
5. Cardiac Amyloidosis Due to Transthyretin Protein: A Review. — Ruberg FL, Maurer MS. The Journal of the American Medical Association. 2024.
6. Cardiomyopathy in Children: Classification and Diagnosis: A Scientific Statement From the American Heart Association. — Lipshultz SE, Law YM, Asante-Korang A, et al. Circulation. 2019.
7. Sudden Death in the Young: Information for the Primary Care Provider. — Erickson CC, Salerno JC, Berger S, et al. Pediatrics. 2021.
8. Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association. — Bogle C, Colan SD, Miyamoto SD, et al. Circulation. 2023.
9. Long-Term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions: A Scientific Statement From the American Heart Association. — Lipshultz SE, Adams MJ, Colan SD, et al. Circulation. 2013.
10. Constrictive Pericarditis Versus Restrictive Cardiomyopathy?. — Garcia MJ. Journal of the American College of Cardiology. 2016.
11. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. — Wilde AAM, Semsarian C, Márquez MF, et al. Heart Rhythm. 2022.
12. Idiopathic Restrictive Cardiomyopathy Is Primarily a Genetic Disease. — Gallego-Delgado M, Delgado JF, Brossa-Loidi V, et al. Journal of the American College of Cardiology. 2016.
13. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. — Kittleson MM, Ruberg FL, Ambardekar AV, et al. Journal of the American College of Cardiology. 2023.
14. Differentiation of Constriction and Restriction: Complex Cardiovascular Hemodynamics. — Geske JB, Anavekar NS, Nishimura RA, Oh JK, Gersh BJ. Journal of the American College of Cardiology. 2016.
15. Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. — Muchtar E, Blauwet LA, Gertz MA. Circulation Research. 2017.
16. Pericardial Diseases and Best Practices for Pericardiectomy: JACC State-of-the-Art Review. — Al-Kazaz M, Klein AL, Oh JK, et al. Journal of the American College of Cardiology. 2024.
17. Restrictive Cardiomyopathy. — Kushwaha SS, Fallon JT, Fuster V. The New England Journal of Medicine. 1997.
18. Multimodality Imaging in Differentiating Constrictive Pericarditis From Restrictive Cardiomyopathy: A Comprehensive Overview for Clinicians and Imagers. — Lloyd JW, Anavekar NS, Oh JK, Miranda WR. Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography. 2023.